Background {#Sec1}
==========

Bloodstream infections (BSI) are potentially life-threatening diseases. BSI was defined as at least 1 positive blood culture for a recognized pathogen and clinical symptoms consistent with bacteraemia. They can cause serious secondary infections, such as infective endocarditis and osteomyelitis, and may result in severe sepsis. Meanwhile, BSI due to multidrug-resistant (MDR) organisms has been associated with multiple poor outcomes, including increased length of hospital stay, health care costs and a high rate of morbidity and mortality.

Tigecycline is a glycylcycline with a broad spectrum of antibacterial activity. The emergence of MDR strains infections has been extensively observed worldwide and has become a priority issue over past decade. Tigecycline is a useful alternative to face the challenges of many MDR organisms. Tigecycline has a large volume of distribution of 7--10 l/kg \[[@CR1]\], penetrating well into different tissues, it has been approved for the treatment of complicated skin and soft-structure infections (cSSSI), complicated intra-abdominal infections (cIAI), and community-acquired bacterial pneumonia (CAP). Tigecycline is not indicated for treatment of diabetic foot infection or for hospital-acquired or ventilator-associated pneumonia \[[@CR2]\]. The use of tigecycline in bacteremia is controversial because of its low serum levels with standard dosing \[[@CR3]\].

Attention should be paid by clinicians, because tigecycline was associated with higher mortality than comparator antibiotics \[[@CR4]--[@CR6]\]. However, a recent meta-analysis showed that the drug was not associated with significantly higher mortality than comparator antibiotics and was as effective as comparators when the analysis was restricted to patients who received tigecycline for approved indications \[[@CR7]\]. A prospective study demonstrates that tigecycline plus prolonged infusion standard-dose imipenem/cilastatin, showed good clinical efficacy on VAP patients with XDR-Ab VAP bacteremia \[[@CR8]\]. The increased mortality associated with tigecycline is not yet well understood in the treatment of BSI. Therefore, we systemically searched and analysed the current available evidence to assess clinical effectiveness of tigecycline for the treatment of BSI.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

Relevant studies were identified through PubMed, Embase and hand-searched from inception until October 2016.The search terms were:"(tigecycline OR TGC OR tygacil) and (bacteraemia OR bacteremia OR bloodstream infection OR sepsis OR septicaemia)". No language restrictions were applied.

Study selection {#Sec4}
---------------

Any article providing the clinical outcomes of patients treated for bloodstream infections caused by any etiological agent was considered eligible for inclusion in the review. Prospective and retrospective observational cohort studies examining the association between tigecycline use (on hospital admission or previous users) and the outcomes of bacteremic patients were included. The outcome of interest was overall hospital mortality at the longest follow-up at each single study. Case reports and case series including fewer than 10 infected patients treated with tigecycline were excluded from the review.

Data extraction {#Sec5}
---------------

The extracted data consisted of the main characteristics of a study (first-author name, year of publication, country, study period, and design), main characteristics and underlying diseases of the study population, number of patients with infections BSI, the causative pathogen(s), sites of infections, and antibiotic treatment (combination therapy or monotherapy). Clinical outcomes (mortality, treatment failure) of patients in each treatment group were recorded as well.

Statistical analysis {#Sec6}
--------------------

We chose mortality as the primary outcome, because of the high mortality rates among patients with BSI, while the secondary outcomes were: clinical response, microbiological response, adverse effects, and emergence of resistance. Microbiological response was defined as successful when eradication or sterile culture results were obtained during or after the antibiotic therapy. Because there are no standard criteria to assess clinical response and adverse events, we accepted the criteria as reported in each study.

All statistical analyses were performed using the comprehensive meta-analysis V2.2 (BioStat, Englewood, NJ). Among the controlled studies, the between-study heterogeneity was assessed using the I^2^ test, whereby I^2^ values \>50% were defined as indicating heterogeneity. Either fixed-effects (Mantel--Haenszel method) or random-effects (DerSimonian and Laird method) models were used, depending on the heterogeneity result. If no heterogeneity was found, meta-analysis was done using the Mantel--Haenszel fixed-effects model. Binary outcomes from controlled studies were expressed as odds ratios (OR) with their 95% confidence intervals (CI), and continuous outcomes were expressed as the mean difference between 2 groups. Egger regression, as well as the Begg methods, was used to evaluate publication bias. All P values were two-tailed, and a P value of ≤0.05 was considered statistically significant. Some statistical analysis was performed by using the SPSS statistical software (version 19; SPSS Inc., Chicago, IL). Categorical variables were evaluated by using the χ^2^ test or 2-tailed Fisher's exact test, as appropriate. Subgroup analyses for mortality and clinical cure were planned for bacteraemic patients. Comparisons were subcategorized by the type of infection. A funnel plot was used to assess small-study effects.

Results {#Sec7}
=======

Literature search results {#Sec8}
-------------------------

1540 potential articles were identified; 56 case reports and clinical series including less than 10 infected patients were excluded; 41 duplicates and 18 single-arm studies were excluded; 22 studies were ruled out because they did not present clear treatment regimens or detailed clinical outcomes; 24 articles were excluded due to few patients in each group. Ultimately 24 studies met the inclusion criteria, 24 controlled studies (1961 patients) included in this systematic review.

Study characteristics {#Sec9}
---------------------

The features of the 24 trials are described in Table [1](#Tab1){ref-type="table"}. Five of them were prospective cohort studies, 7 were retrospective studies. All of the included controlled studies had an NOS score \>3. Most patients in the included studies were critically ill, with most of them in ICU.Table 1Characteristics of included studiesReferenceStudy yearsLocationType of studyType of infectionCausative pathogen(s)Mortality assessedSample size(no.of tigecycline/control patients)Concomitant antibiotics administeredin tigecycline groupCompatatorTigecycline doseControl regimen doseOliva et al. \[[@CR22]\]NaMulticenterProspective, double-blind phase 3cIAI with bacteremiaMixUndetermined14/27NoneImipenem cilastatinInitial dose of 100 mg, followed by 50 mg every 12 h500 mg followed by 500 mg per 6 h combined imipenem and cilastatinMcGovern et al. \[[@CR11]\]2001--08USAComparative studies, phase 3 and 4BacteremiaMixOverall162/163NaNaNaNaDaikos et al. \[[@CR23]\]2009--10GreeceRetrospectiveBSICP-KpAt 28 days94/81Colistin aminoglycoside carbapenemColistin aminoglycoside carbapenemFor tigecycline the total daily dose was 100--200 mg administered in two divided dosages1 g imipenem and meropenem every 8 h, 5 mg/kg gentamicin and amikacin once dailyJean et al. \[[@CR8]\]2013TaiwanProspectiveVAP with bacteremiaXDR-AbAt 14 days28/56Ipipenem/cilastaSulbactam + imipenem/cilastatinNaNaFlorescu et al. \[[@CR24]\]2003--05MulticenterDouble-blind, phase 3BacteremiaMRSA VREAt 12--37 days after the last dose14/20NoneVancomycin or linezolidInitial dose of 100 mg, followed by 50 mg every 12 h1 g per 12 h followed by 600 mg per 12 h vancomycin plus linezolidSacchidanand et al. \[[@CR25]\]NaMulticenterRandomized, double-blind, phase 3cSSSI with bacteremiaXDR-AbOverall8/22NoneVancomycin plus aztreonamInitial dose of 100 mg, followed by 50 mg every 12 h1 g per 12 h followed by 2 g per 12 h vancomycin plus aztreonamLiou et al. \[[@CR26]\]2007--13TaiwanRetrospectiveSecondary bacteremiaAcinetobacterAt 14 days17/65Ampicillin-sulbactam sulbactam levofloxacin ceftazidimeNaStandard dose of tigecyclineNaCheng et al. \[[@CR27]\]2010--13TaiwanProspectiveBacteremiaXDR-AbAt discharge29/55ColistinColistin carbapenemInitial dose of 100 mg, followed by 50 mg every 12 h2.5--5 mg/kg/d of colistin base divided over 8 or 12 hTanaseanu et al. \[[@CR28]\]2003--05MulticenterRandomized, double-blind, phase 3CAP with bacteremia*Streptococcus pneumoniae*At 7--23 days after the last dose22/40NoneLevofloxacinInitial dose of 100 mg, followed by 50 mg every 12 h500 mg every 24 h levofloxacinTumbarello et al. \[[@CR29]\]2010--11ItalyRetrospectiveBSIKPC-KpAt 30 days70/48Colistin gentamicin meropenemColistin gentamicin meropenemEvery 12 h (100--200 mg/day)Every 8--12 h for a total daily dose of 6,000,000--9,000,000 IU colistin; 4--5 mg/kg every 24 h gentamicin; 2 g every 8 h meropenemZarkotou et al. \[[@CR30]\]2008--10GreeceObservationalBSIKPC-KpOverall22/13Colistin gentamicin carbapenem amikacinColistin gentamicin carbapenemNaNaBucaneve et al. \[[@CR31]\]2008--10MulticenterProspective, open-labelBacteremiaMixOverall86/94Piperacillin/tazobactamPiperacillin/tazobactamInitial dose of 100 mg, followed by 50 mg every 12 h4.5 g piperacillin/tazobactam every 8 hPapadimitriou-Olivgeris et al. \[[@CR32]\]NaGreeceSingle-centre observational studyBSIKPC-KpAt 30 days27/9Colistin gentamicinColistin gentamicinNaNaGardiner et al. \[[@CR19]\]NaMulticenterRetrospective, randomized, 7 double-blind and 1 open-label, phase 3BacteremiaMixNa91/79NaNaNaNaBreedt et al. \[[@CR33]\]2002--03MulticenterRandomized, double-blind, phase 3cSSSI with bacteremiaMixOverall15/10NoneVancomycin-aztreonamInitial dose of 100 mg, followed by 50 mg every 12 h1 g vancomycin plus 2 g aztreonam per 12 hBabinchak et al. \[[@CR34]\]2002--04MulticenterRandomized, double-blind, phase 3cIAI with bacteremiaMixOverall40/50NoneImipenem-cilastatinInitial dose of 100 mg, followed by 50 mg every 12 h500 mg followed by 500 mg per 6 h combined imipenem and cilastatinEllis-Grosse et al. \[[@CR35]\]2001--04MulticenterRandomized, double-blind, phase 3cSSSI with bacteremiaMixOverall23/24NoneVancomycin-aztreonamInitial dose of 100 mg, followed by 50 mg every 12 h1 g vancomycin plus 2 g aztreonam per 12 hFomin et al. \[[@CR36]\]NaMulticenterDouble-blind, phase 3cIAI with bacteremiaMixNa26/23NoneImipenem-cilastatinInitial dose of 100 mg, followed by 50 mg every 12 h500 mg followed by 500 mg per 6 h combined imipenem and cilastatinDartois et al. \[[@CR37]\]NaMulticenterDouble-blind, phase 3CAP with\
bacteremiaMixOverall32/31NoneLevofloxacinInitial dose of 100 mg, followed by 50 mg every 12 h500 mg per 24 h or per 12 h levofloxacinQureshi et al. \[[@CR38]\]2005--09USARetrospectiveBacteremiaKPC-KpAt 28 days11/23Carbapenem aminoglycosideCarbapenem gentamicin cefepime et al.NaNaLauf et al. \[[@CR39]\]2006--09MulticenterRandomized, double-blind, phase 3BacteremiaMixNa7/14NoneErtapenem ± vancomycin150 mg once-daily tigecycline1 g once-daily ertapenem ± vancomycinGomez-Simmonds et al. \[[@CR40]\]2006--13USARetrospectiveBSICR-KpAt 30 days26/42Beta-lactam antibioticPolymyxin b aminoglycosideInitial dose of 100 mg, followed by 50 mg every 12 hNaMaki et al. \[[@CR41]\]2007USAProspectiveBacteremiaCVC-CoNSNa8/23NaVancomycin50 mg every 12 hNaOliveira et al. \[[@CR42]\]2009--13BrazilRetrospectiveBacteremiaKPC-EnterobacteriaceaeAt 30 days15/62Carbapenem polymyxin aminoglycosideCarbapenem polymyxin aminoglycosideNaNaBSI, bloodstream infection; cIAI, complicated intra-abdominal infections; cSSSI, complicated skin and skin-structure infections; CAP, community-acquired pneumonia; CR-Kp, carbapenem-resistant *K. pneumoniae*; CVC-CoNS, central venous catheter-related coagulase-negative staphylococcal; KPC-Kp, *Klebsiella pneumoniae* carbapenemase-producing *K. pneumoniae*; MRSA, methicillin-resistant *Staphylococcus aureus*; Na, not available; VAP, ventilator-associated pneumonia; VRE, vancomycin-resistant enterococci; XDR-Ab, extensively drug-resistant *Acinetobacter baumannii*

Mortality {#Sec10}
---------

As shown in Fig. [1](#Fig1){ref-type="fig"}, no significant difference was noted when tigecycline was compared with control groups in terms of all-cause mortality (14 studies; 1502 patients) \[OR 0.841, 95% confidence interval (CI) 0.517--1.367; P = 0.485\]. Because statistical heterogeneity existed among studies (X^2^ = 32.76, df = 13, (P = 0.002), I^2^ = 60.3%), a random-effects model of analysis was used. No publication bias was detected by Egger regression (t = −0.39; df = 12.0; P = 0.701) or Begg (z = 0.55; df = 12.0; P = 0.584).Fig. 1Mortality with tigecycline versus other antibiotics therapy

Table [2](#Tab2){ref-type="table"} shows the subgroup analysis of the controlled studies. A significant difference was observed between the tigecycline monotherapy therapy group and the tigecycline combination therapy group in terms of mortality (6 studies; 250 patients) (OR 2.733, \[95% CI 1.533--4.873; P = 0.001\]; I^2^ = 8.7%). A significantly higher mortality was noted in the monotherapy group than in the combination therapy group in cases of blood stream infection. The mortality in the combination of tigecycline plus colistin based group was not significantly lower than that in the other antibiotics combination group (OR 0.68, \[95% CI 0.407--1.135; P = 0.14\]; I^2^ = 0.0%).Table 2Subgroup analysis of overall mortality with tigecycline versus other antibiotics for treatment of bloodstram infections in controlled studiesVariablesStudies, no. (patients, no.)Mortality of tigecycline compared with control OR (95% CI); PHeterogeneity of studiesMonotherapy vs combination6 (250)2.733 (1.533--4.873); 0.001X^2^ = 5.47, df = 5, (P = 0.361), I^2^ = 8.7%Tigecycline plus polymyxins based vs other antibiotics combination5 (289)0.680 (0.407--1.135); 0.140X^2^ = 2.88, df = 4, (P = 0.578), I^2^ = 0.0%Kp BSI6 (466)0.678 (0.457--1.006); 0.054X^2^ = 3.95, df = 5, (P = 0.556), I^2^ = 0.0%KPC-Kp BSI5 (398)0.636 (0.417--0.971); 0.036X^2^ = 3.31, df = 4, (P = 0.507), I^2^ = 0.0%Acinetobacter BSI3 (221)0.967 (0.096--9.759); 0.978X^2^ = 23.76, df = 2, (P = 0.001), I^2^ = 91.6%CI, confidence interval; OR, odds ratio

In the patients infected with *Klebsiella pneumoniae* (Kp) BSI, tigecycline seemed to have a lower mortality than comparator drugs, but the difference was not significant (OR 0.678, \[95% CI 0.457--1.006; P = 0.054\]; I^2^ = 0.0%; \[P = 0.556\]). Five studies (398 patients) reported data on carbapenemase-producing Kp BSI, and a significant difference with respect to overall mortality was observed between the tigecycline therapy group and the controls (OR 0.636, \[95% CI 0.417--0.971; P = 0.036\]; I^2^ = 0.0%; \[P = 0.507\]). Three controlled studies (221 patients) reported Acinetobacter BSI, no difference was seen between patients who received tigecycline as therapy and others in mortality (OR 0.967, \[95% CI 0.096--0.759; P = 0.978\]; I^2^ = 91.6%; \[P = 0.001\]).

Clinical cure {#Sec11}
-------------

There was a significant differences were observed between the tigecycline and control groups in this regard (OR 1.76, \[95% CI 1.26--2.45; P = 0.001\]; I^2^ = 29.2%; \[P = 0.159\]; Fig. [2](#Fig2){ref-type="fig"}). Clinical cure was significantly higher in the tigecycline population. In the subgroup analysis, for analysis by type of infection, without statistical significance was found in patients with cIAI (OR 0.97, \[95% CI 0.52--1.80; P = 0.919\]; I^2^ = 0.0%; \[P = 0.953\]) and cSSSI (OR 0.71, \[95% CI 0.26--1.90; P = 0.494\]; I^2^ = 0.0%; \[P = 0.821\]), but in trials assessing patients with CAP, for the rate of clinical cure, the efficacy of tigecycline was better than that of comparator regimens (OR 2.44, \[95% CI 1.20--4.94; P = 0.013\]; I^2^ = 0.0%; \[P = 0.821\]). As shown in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2The efficacy of tigecycline, as compared with other antibiotics, in treating infections caused by BSI

Microbiological response {#Sec12}
------------------------

As shown in Fig. [2](#Fig2){ref-type="fig"}, tigecycline group did not differ significantly compared with the comparators in the rate of microbiological success (OR 2.07, \[95% CI 0.56--7.70; P = 0.279\]; I^2^ = 0.0%; \[P = 0.854\]) (Fig. [2](#Fig2){ref-type="fig"}).

Adverse effects {#Sec13}
---------------

There were not sufficiently effective data to be recoded, so that the common adverse effects of tigecycline (nausea, vomiting, and diarrhea) could not be extracted in any of the studies.

Discussion {#Sec14}
==========

We conducted this systematic review and meta-analysis to investigate the effectiveness and safety of tigecycline for the treatment of BSI. Numerous studies have established bacteremia as a marker of severe infection and a risk for adverse outcomes in multiple treatment settings \[[@CR9], [@CR10]\], but there were some positive elements about the treatment of BSI with tigecycline.

To our knowledge, this was the first systematic review to assess the efficacy of tigecycline in treating BSI. Although all-cause mortality was lower with tigecycline than with the control regimens, the difference was not significant. Tigecycline seemed to be better than levofloxacin for treatment of community-acquired pneumonia, and worse than control regimens for cIAI and cSSSI, but these differences were not significant. However, drug safety guidelines published by the FDA refer to an increased mortality risk associated with intravenous tigecycline compared with other drugs used to treat serious infections (risk difference = 0.6%, 95% CI 0.1--1.2) \[[@CR2]\]. This result has been confirmed by a study that associated the increased risk mortality with resistant pathogens, hospital-acquired pneumonia, and increased age of patients \[[@CR11]\]. However the type of serious infections didn't include BSI. We used the same effect metric to assess our results, and noted that the risk difference of all-cause mortality was not significant (−3.5%, 95% CI −13 to −6; I^2^ = 85.4%, P = 0.001).

Although the overall mortality did not differ between tigecycline and the control groups, subgroup analysis found the mortality was significantly lower in the tigecycline combination group than in the tigecycline monotherapy therapy group. Tigecycline in combination with colistin, carbapenem in combination with colistin, and tigecycline in combination with gentamicin were the commonly administered antibiotic treatment regimens among the included studies and might result in lower mortality than other combinations of antibiotics. The most common combination was tigecycline with colistin in tigecycline combination therapy group, yet this data did not necessarily predict tigecycline plus polymyxins based therapy was significantly better than other antibiotics combination therapy. For the patients with KPC-Kp BSI, antibiotic therapy with tigecycline was associated with lower mortality.

With regard to clinical response, the evidence that we could compile from studies was that tigecycline therapy may have no clinical advantage over comparator therapy, but may result in better clinical cure in treatment of CAP presenting with bacteremia.

Tigecycline had good eradication ability for most pathogens recorded at baseline, as a novel glycylcycline antibiotic, it has a broad spectrum of antimicrobial activity, ranging from aerobic to anaerobic bacteria, and gram-positive, gram-negative (exceptions of *Pseudomonas aeruginosa* and *Proteus mirabilis*), and atypical organisms \[[@CR12]\]. Eradication was better than with control regimens in all cases, although no significant difference was found when tigecycline was compared with the comparators.

Previous studies have shown that the most common adverse effects of tigecycline had increased incidence in the tigecycline group, such as nausea, vomiting, and diarrhea \[[@CR13], [@CR14]\]. According to a recently published review, tigecycline induces acute pancreatitis, indicating that surveillance for adverse events from the digestive system is needed during treatment \[[@CR15]\]. But lack of data from all trials results can not be obtained about adverse events outcomes in our meta-analysis.

Small non-comparative series have reported relatively poor clinical and microbiological outcomes with tigecycline for tigecycline-susceptible CR-Ab bacteremia \[[@CR16]--[@CR18]\]. The high severity of illness and the notable delays in initiation of effective antimicrobial therapy could also explain these results. In a pooled, retrospective data analysis of phase 3 clinical trials, 91 patients being treated with tigecycline had secondary bacteremia detected, tigecycline appeared safe and well tolerated in the treatment of secondary bacteremia associated with cSSSI, cIAI, and CAP; cure rates were similar to comparative standard therapies \[[@CR19]\]. Recently, a high-dose regimen (loading dose 200 mg followed by 100 mg every 12 h) has been successfully and safely used in critically ill patients with severe infections due to multi drug resistant bacteria although the number of primary bacteremia was anecdotal \[[@CR20]\].

Several potential limitations should be taken into consideration when interpreting the present results. Firstly, the number of subjects included was not large enough. We would have preferred to contact researchers directly for missing data, but this approach was not attempted because of time constraints. Secondly, in some subgroup analyses, the sample size was small, which may have reduced the power of the statistical analysis. Another important issue is that the administrations of the antibiotics differed among the studies with regard to the duration of infusion or the total daily dose. Thirdly, due to the included studies did not provide relevant data, we were unable to assess the impact of tigecycline on adverse drug reactions. Accordingly, these differences might influence the clinical outcomes. Last, the matter of the emergence of resistance during therapy was not raised by any of the included studies.

In conclusion, based on a review of published cases, tigecycline appears to have produced some favourable clinical and microbiological outcomes in patients with BSI, even when used as monotherapy. This research was needed to clarify whether tigecycline was suitable for treatment such infections when other antibiotics fail, especially because indications for increased risk of all-cause mortality have been reported in patients treated with this drug. The FDA has recently reported an increased risk of death when intravenous tigecycline is used for FDA approved purposes \[[@CR21]\], which may be explained by a worsening infection or potential complications \[[@CR11]\].

The available evidence suggests that combination antibiotic treatment may offer a comparative advantage over monotherapy with regard to the mortality of critically ill patients with severe infections due to BSI. The number of currently available appropriate antimicrobial agents is limited, combination therapy with tigecycline, it could be a fine option for the treatment of BSI, especially in patients with KPC-Kp BSI.
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